1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/18 12:45:35 pm
142.52 USD   -2.75%
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

01/18/2022 | 05:00pm EDT

Seagen Inc. announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San Francisco, January 20 – 22, 2022. SEA-CD40 is a novel, investigational, nonfucosylated monoclonal receptor-agonistic antibody directed to CD40, which is expressed on antigen-presenting cells. In preclinical models, the combination of SEA-CD40 and chemotherapy resulted in antitumor activity which is further enhanced with anti-PD-1 treatment. In the ongoing phase 1 trial, SEA-CD40 was combined with chemotherapy [gemcitabine and nab-paclitaxel (GnP)], and an anti-PD-1 (pembrolizumab), in 61 patients with untreated metastatic PDAC. Of these, 40 patients received 10 mcg/kg and 21 patients received 30 mcg/kg of SEA-CD40. Key endpoints include confirmed objective response rate (cORR) per RECIST v1.1 by investigator, progression-free survival (PFS) and overall survival (OS). Activity of SEA-CD40 in combination with GnP and pembrolizumab was observed in both doses of SEA-CD40 tested. The overall (N = 61) cORR was 44 percent, median PFS was 7.4 months (95% CI: 5.6-9.0), and median OS was 15.0 months (95 percent CI: 7.8-19.9). Follow-up for efficacy is ongoing. The regimen demonstrated a manageable and tolerable safety profile. Overall, = grade 3 treatment-emergent adverse events (TEAEs) were fatigue, nausea, neutropenia, infusion-related reaction, chills, diarrhea, and pyrexia. This combination also showed evidence of immune activation consistent with the SEA-CD40 mechanism of action.


ę S&P Capital IQ 2022
All news about SEAGEN INC.
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
05/16INSIDER SELL : Seagen
MT
05/16SEAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
05/16Seagen's President, CEO Clay Siegall Resigns Amid Investigation
MT
05/16Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
BU
05/16Seagen Announces Resignation of Clay Siegall as CEO
CI
05/09SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close
MT
05/09SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 792 M - -
Net income 2022 -648 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -42,0x
Yield 2022 -
Capitalization 26 976 M 26 976 M -
EV / Sales 2022 14,2x
EV / Sales 2023 10,1x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 146,55 $
Average target price 160,17 $
Spread / Average Target 9,29%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Marc E. Lippman Independent Director
Felix James Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-5.21%26 976
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
ICON PUBLIC LIMITED COMPANY-32.47%17 002
ALNYLAM PHARMACEUTICALS, INC.-26.37%15 622